NCT07463287 High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
| NCT ID | NCT07463287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai East Hospital |
| Condition | MASH - Metabolic Dysfunction-Associated Steatohepatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-04-30 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-04-30 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of MAFLD conforms to the "Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease" (2018 Edition); 2. Male or female patients aged 18-70 years; 3. Signed informed consent form and explanation of the specific study protocol. Exclusion Criteria: 1. Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer; 2. Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders; 3. Individuals lacking legal capacity or with poor insight.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07463287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying MASH - Metabolic Dysfunction-Associated Steatohepatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07463287 currently recruiting?
Yes, NCT07463287 is actively recruiting participants. Contact the research team at 13487975691@qq.com for enrollment information.
Where is the NCT07463287 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07463287 clinical trial?
NCT07463287 is sponsored by Shanghai East Hospital. The trial plans to enroll 100 participants.